From a biological point of view, locoregional treatments have been suggested to upregulate vascular endothelial growth factor (VEGF) [13,14]; since VEGF has a crucial role in the pathogenesis of HCC, antiangiogenic agents have been tested in combination with locoregional therapies [15,16]. Here, VEGFA is linked to hepatocellular carcinoma.